Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J advises following labels

This article was originally published in The Tan Sheet

Executive Summary

Following the death of a Staten Island, N.Y. teenager caused by overuse of Bengay and other OTC anti-inflammatory muscle creams and other products, Johnson & Johnson advised consumers to follow label instructions on all OTCs. In a statement, J&J says Bengay "should be applied to the affected area not more than 3-4 times daily and consumers should stop use and see a doctor if the condition worsens or if symptoms persist for more than seven days." On June 9, the New York City Medical Examiner's Office stated 17-year old Arielle Newman died April 3 from an accidental overdose of methyl salicylate, the active ingredient in Bengay and other sports balms. An office spokesperson says continuous overuse created a toxic level of methyl salicylate in the girl's system. In addition to using the creams between track meets, the girl was using adhesive pads with methyl salicylate and an unknown third product containing the anti-inflammatory ingredient, the spokesperson says, adding it is the office's first reported death caused by sports cream...

You may also be interested in...



Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.

Balancing Innovation And Safety – The US and Australian Medtech Regulatory Systems Compared

Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.

UK Responsible Person, EU ARs and Northern Ireland: The View From MedTech Europe

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel